BRPI1009860A2 - composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais - Google Patents

composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais

Info

Publication number: BRPI1009860A2
Authority: BR; Brazil
Prior art keywords: humans; animals; disease; prevention; compound
Prior art date: 2009-03-16

Application number

BRPI1009860A

Other languages

English (en)

Inventor

Amaia Marcilla Etxnike

Daniel Horacio López

Gwendolyn Barceló Coblijn

María Laura Martín

Mónica Higuera Urbano

Pablo Vicente Escribá Ruiz

Rafael Álvarez Martínez

Silvia Terés Jiménez

Victoria Lladó Cañellas

Xavier Busquets Xaubet

Original Assignee

Lipopharma Therapeutics S L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-16

Filing date

2010-03-15

Publication date

2016-03-08

2010-03-15 Application filed by Lipopharma Therapeutics S L filed Critical Lipopharma Therapeutics S L

2016-03-08 Publication of BRPI1009860A2 publication Critical patent/BRPI1009860A2/pt

2019-12-17 Publication of BRPI1009860A8 publication Critical patent/BRPI1009860A8/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI1009860A 2009-03-16 2010-03-15 composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais BRPI1009860A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES200900725A ES2345241B1 (es)	2009-03-16	2009-03-16	Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
PCT/ES2010/070153 WO2010106211A1 (es)	2009-03-16	2010-03-15	Uso de derivados de ácidos grasos poliinsaturados como medicamentos

Publications (2)

Publication Number	Publication Date
BRPI1009860A2 true BRPI1009860A2 (pt)	2016-03-08
BRPI1009860A8 BRPI1009860A8 (pt)	2019-12-17

Family

ID=42673244

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1009860A BRPI1009860A8 (pt)	2009-03-16	2010-03-15	composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais

Country Status (18)

Country	Link
US (7)	US9161928B2 (pt)
EP (2)	EP3159329B1 (pt)
JP (1)	JP5904592B2 (pt)
KR (4)	KR20180021931A (pt)
CN (4)	CN109999018A (pt)
AU (6)	AU2010224749B2 (pt)
BR (1)	BRPI1009860A8 (pt)
CA (1)	CA2754963C (pt)
CL (1)	CL2011002268A1 (pt)
DK (2)	DK3159329T3 (pt)
ES (3)	ES2345241B1 (pt)
HU (2)	HUE032027T2 (pt)
MX (1)	MX2011009614A (pt)
PL (1)	PL2409963T3 (pt)
PT (2)	PT2409963T (pt)
RU (1)	RU2513995C2 (pt)
SI (1)	SI3159329T1 (pt)
WO (1)	WO2010106211A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2345241B1 (es)	2009-03-16	2011-09-08	Lipopharma Therapeutics	Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
DK2493296T3 (en)	2009-10-30	2019-04-15	Retrotope Inc	REMOVAL OF OXIDATIVE STRESS STATES WITH PUFA DERIVATIVES
WO2012148929A2 (en)	2011-04-26	2012-11-01	Retrotope, Inc.	Disorders implicating pufa oxidation
US10154983B2 (en) *	2011-04-26	2018-12-18	Retrotope, Inc.	Neurodegenerative disorders and muscle diseases implicating PUFAs
KR102020579B1 (ko)	2011-04-26	2019-09-10	레트로토프 인코포레이티드	에너지 프로세싱 손상 장애 및 미토콘드리아 결함
US10058522B2 (en)	2011-04-26	2018-08-28	Retrotope, Inc.	Oxidative retinal diseases
ES2401629B1 (es) *	2011-10-07	2014-03-04	Universitat De Les Illes Balears	Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
JP6348229B2 (ja) *	2014-10-21	2018-06-27	ユニバーシタットデレスイレスバレアレス	ヒドロキシ−トリグリセリドの合成方法、および疾患の予防および処置のためのその使用
EP3267200A4 (en) *	2015-03-06	2018-08-22	Niigata University	Biomarker of dementia with lewy bodies
WO2017091279A1 (en)	2015-11-23	2017-06-01	Retrotope, Inc.	Site-specific isotopic labeling of 1, 4-diene systems
GB201521085D0 (en) *	2015-11-30	2016-01-13	Biozep As	Use
AU2018269462B2 (en) *	2017-05-16	2024-04-18	Ability Pharmaceuticals S.L.	A pharmaceutical combination for the treatment of a cancer
WO2019157516A1 (en)	2018-02-12	2019-08-15	resTORbio, Inc.	Combination therapies
US10980784B2 (en)	2018-06-15	2021-04-20	Navitor Pharmaceuticals, Inc.	Rapamycin analogs and uses thereof
EP4069223A4 (en)	2019-12-05	2023-12-20	Janssen Pharmaceutica NV	RAPAMYCIN ANALOGS AND THEIR USES
ES2846824B2 (es) *	2020-01-29	2022-01-19	Univ Illes Balears	Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
IL295120A (en) *	2020-01-29	2022-09-01	Univ Illes Balears	alpha-hydroxylated fatty-acid metabolites, their medical uses and their use as biomarkers
IL295067A (en)	2020-02-10	2022-09-01	Ability Pharmaceuticals S L	Pharmaceutical combination for cancer treatment
EP4107163A4 (en)	2020-02-21	2024-06-19	Retrotope, Inc.	PROCESSES FOR ISOTOPIC MODIFICATION OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES
US12109194B2 (en)	2021-02-05	2024-10-08	Biojiva Llc	Synergistic combination therapy for treating ALS
US11491130B2 (en)	2021-02-05	2022-11-08	Retrotope, Inc.	Methods of treating amyotrophic lateral sclerosis

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8717816D0 (en)	1987-07-28	1987-09-03	Manchester Inst Science Tech	Fabric testing apparatus
GB2218984B (en) *	1988-05-27	1992-09-23	Renafield Limited	Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
JPH05974A (ja) *	1991-06-21	1993-01-08	Sagami Chem Res Center	ハロゲン化不飽和アルキル化合物及びその前駆体
ES2161146B1 (es) *	1999-06-29	2002-07-01	Consejo Superior Investigacion	Compuestos antimicrobianos, uso y metodo para inducir resistencia a infecciones de bacterias en plantas.
US6344574B1 (en)	2000-07-20	2002-02-05	The United States Of America As Represented By The Secretary Of Agriculture	Solvent fractionation of chicken fat for making lipid compositions enriched in unsaturated fatty acid-containing triacylglycerols
DE10106660A1 (de) *	2001-02-12	2002-08-29	Celanese Ventures Gmbh	Verfahren zur Herstellung von gamma-Linolensäure aus einer Ciliaten-Kultur durch Zusatz geeigneter Vorläufermoleküle zu dem Kulturmedium
ES2186576B1 (es) *	2001-10-11	2004-09-16	Universitat De Les Illes Balears	Acido 2-hidroxioleico para utilizar como medicamento.
US6949664B2 (en) *	2002-04-01	2005-09-27	University Of Southern California	Trihydroxy polyunsaturated eicosanoids
US7135575B2 (en) *	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
CA2588166A1 (en) *	2004-11-19	2006-05-26	Martek Biosciences Corporation	Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
GB0428384D0 (en) *	2004-12-24	2005-02-02	Sla Pharma Ag	Eicosapentaenoic acid
US8324276B2 (en)	2005-01-24	2012-12-04	Pronova Biopharma Norge As	Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
JP5337479B2 (ja)	2005-05-04	2013-11-06	プロノヴァ・バイオファーマ・ノルゲ・アーエス	新規化合物
CN101213281B (zh) *	2005-05-04	2013-03-13	普罗诺瓦生物医药挪威公司	新的dha衍生物及其作为药物的用途
US8059805B2 (en) *	2005-06-30	2011-11-15	Emc Corporation	Enhanced services provided using communication redirection and processing
KR20130101596A (ko)	2005-07-08	2013-09-13	마텍 바이오싸이언스스 코포레이션	치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산
EP1772146A1 (en)	2005-10-03	2007-04-11	Neuropharma, S.A.	Polyunsaturated fatty acids as bace inhibitors
WO2007058523A1 (en) *	2005-11-17	2007-05-24	N.V. Nutricia	Composition with docosapentaenoic acid
ATE509624T1 (de) *	2005-12-23	2011-06-15	Nutricia Nv	Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
US8399516B2 (en) *	2006-11-01	2013-03-19	Pronova Biopharma Norge As	Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR)
WO2008142482A2 (en)	2006-11-01	2008-11-27	Pronova Biopharma Norge As	Omega-3 lipid compounds
WO2008053340A1 (en) *	2006-11-03	2008-05-08	Pronova Biopharma Norge As	A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
US20080234377A1 (en) *	2007-03-23	2008-09-25	Martek Biosciences Corporation	Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
ES2345241B1 (es)	2009-03-16	2011-09-08	Lipopharma Therapeutics	Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
ES2401629B1 (es) *	2011-10-07	2014-03-04	Universitat De Les Illes Balears	Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.

2009
- 2009-03-16 ES ES200900725A patent/ES2345241B1/es active Active
2010
- 2010-03-15 RU RU2011141850/04A patent/RU2513995C2/ru active
- 2010-03-15 KR KR1020187005245A patent/KR20180021931A/ko not_active Ceased
- 2010-03-15 KR KR1020207005917A patent/KR102233102B1/ko active Active
- 2010-03-15 CN CN201910095352.2A patent/CN109999018A/zh active Pending
- 2010-03-15 BR BRPI1009860A patent/BRPI1009860A8/pt active Search and Examination
- 2010-03-15 EP EP16201132.4A patent/EP3159329B1/en active Active
- 2010-03-15 KR KR1020117024210A patent/KR101833772B1/ko active Active
- 2010-03-15 JP JP2012500281A patent/JP5904592B2/ja active Active
- 2010-03-15 DK DK16201132.4T patent/DK3159329T3/da active
- 2010-03-15 WO PCT/ES2010/070153 patent/WO2010106211A1/es not_active Ceased
- 2010-03-15 CN CN201610773061.0A patent/CN106349058B/zh active Active
- 2010-03-15 PT PT107531584T patent/PT2409963T/pt unknown
- 2010-03-15 MX MX2011009614A patent/MX2011009614A/es active IP Right Grant
- 2010-03-15 CN CN2010800119398A patent/CN102356057A/zh active Pending
- 2010-03-15 KR KR1020197004239A patent/KR20190018754A/ko not_active Ceased
- 2010-03-15 PT PT162011324T patent/PT3159329T/pt unknown
- 2010-03-15 US US13/257,128 patent/US9161928B2/en active Active
- 2010-03-15 HU HUE10753158A patent/HUE032027T2/en unknown
- 2010-03-15 ES ES16201132T patent/ES2820025T3/es active Active
- 2010-03-15 HU HUE16201132A patent/HUE051850T2/hu unknown
- 2010-03-15 EP EP10753158.4A patent/EP2409963B1/en active Active
- 2010-03-15 AU AU2010224749A patent/AU2010224749B2/en not_active Revoked
- 2010-03-15 DK DK10753158.4T patent/DK2409963T3/en active
- 2010-03-15 SI SI201032041T patent/SI3159329T1/sl unknown
- 2010-03-15 ES ES10753158.4T patent/ES2613606T3/es active Active
- 2010-03-15 PL PL10753158T patent/PL2409963T3/pl unknown
- 2010-03-15 CN CN201610773030.5A patent/CN106420686B/zh active Active
- 2010-03-15 CA CA2754963A patent/CA2754963C/en active Active
2011
- 2011-09-13 CL CL2011002268A patent/CL2011002268A1/es unknown
2015
- 2015-09-29 US US14/869,045 patent/US9763906B2/en active Active
- 2015-09-29 US US14/869,080 patent/US9763907B2/en active Active
2016
- 2016-07-13 US US15/209,540 patent/US9907772B2/en active Active
- 2016-10-07 AU AU2016238970A patent/AU2016238970B2/en not_active Revoked
2017
- 2017-08-22 US US15/683,379 patent/US10201515B2/en active Active
2018
- 2018-06-05 AU AU2018203976A patent/AU2018203976B2/en not_active Expired - Fee Related
- 2018-12-18 US US16/224,262 patent/US20190365690A1/en not_active Abandoned
2019
- 2019-09-06 AU AU2019226257A patent/AU2019226257B2/en active Active
2020
- 2020-04-22 US US16/855,463 patent/US11253497B2/en active Active
- 2020-07-13 AU AU2020205214A patent/AU2020205214B2/en active Active
- 2020-07-13 AU AU2020205213A patent/AU2020205213B2/en active Active

Also Published As

Publication number	Publication date
US20170035720A1 (en)	2017-02-09
US11253497B2 (en)	2022-02-22
AU2016238970A1 (en)	2016-11-03
CN106420686B (zh)	2020-05-22
KR101833772B1 (ko)	2018-03-02
MX2011009614A (es)	2012-01-20
KR20180021931A (ko)	2018-03-05
US9161928B2 (en)	2015-10-20
CN102356057A (zh)	2012-02-15
ES2820025T3 (es)	2021-04-19
PL2409963T3 (pl)	2017-05-31
HK1232207A1 (zh)	2018-01-05
EP2409963A1 (en)	2012-01-25
US20200352891A1 (en)	2020-11-12
KR102233102B1 (ko)	2021-03-26
KR20200024953A (ko)	2020-03-09
JP2012520344A (ja)	2012-09-06
US20120108550A1 (en)	2012-05-03
US9763907B2 (en)	2017-09-19
DK2409963T3 (en)	2017-02-27
KR20190018754A (ko)	2019-02-25
SI3159329T1 (sl)	2021-01-29
US9763906B2 (en)	2017-09-19
HUE051850T2 (hu)	2021-03-29
RU2011141850A (ru)	2013-04-27
KR20110137365A (ko)	2011-12-22
PT2409963T (pt)	2017-02-15
ES2345241A1 (es)	2010-09-17
AU2019226257A1 (en)	2019-09-26
EP2409963A4 (en)	2013-10-02
AU2020205213B2 (en)	2021-02-25
US10201515B2 (en)	2019-02-12
CL2011002268A1 (es)	2012-01-27
CA2754963C (en)	2022-02-08
US20180085332A1 (en)	2018-03-29
CN106420686A (zh)	2017-02-22
CA2754963A1 (en)	2010-09-23
DK3159329T3 (da)	2020-11-09
US20190365690A1 (en)	2019-12-05
US20160158180A1 (en)	2016-06-09
ES2345241B1 (es)	2011-09-08
EP2409963B1 (en)	2017-01-04
AU2010224749B2 (en)	2016-07-07
AU2010224749A1 (en)	2011-10-13
AU2018203976B2 (en)	2019-06-06
US9907772B2 (en)	2018-03-06
HUE032027T2 (en)	2017-08-28
AU2019226257B2 (en)	2020-05-07
PT3159329T (pt)	2020-11-13
ES2613606T3 (es)	2017-05-24
BRPI1009860A8 (pt)	2019-12-17
EP3159329B1 (en)	2020-08-12
CN106349058A (zh)	2017-01-25
CN106349058B (zh)	2020-01-14
EP3159329A1 (en)	2017-04-26
AU2020205214B2 (en)	2021-02-18
AU2018203976A1 (en)	2018-06-21
AU2016238970B2 (en)	2018-03-08
JP5904592B2 (ja)	2016-04-13
WO2010106211A1 (es)	2010-09-23
CN109999018A (zh)	2019-07-12
US20160158181A1 (en)	2016-06-09
AU2020205213A1 (en)	2020-07-30
RU2513995C2 (ru)	2014-04-27
AU2020205214A1 (en)	2020-07-30

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2019-01-15	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-04-24	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-07-30	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-01-28	B09B	Patent application refused [chapter 9.2 patent gazette]
2020-06-09	B12B	Appeal against refusal [chapter 12.2 patent gazette]
2026-04-28	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2026-08-11	B09A	Decision: intention to grant [chapter 9.1 patent gazette]

Publication	Publication Date	Title
BRPI0822162A8 (pt)	2015-09-22	método para tratamento de doenças das unhas ou leito ungueal e composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal.
BRPI0820568A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
BRPI1009381A2 (pt)	2016-06-21	compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
BR112015003332A2 (pt)	2017-09-26	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt)	2018-04-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
PT3058875T (pt)	2022-09-20	Sistema para tratamento cosmético e imagiologia
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BRPI1009252A2 (pt)	2016-03-15	composto, pró-droga, composição farmacêutica, métodos para prevenir ou tratar doenças do sistema nervoso central, e mal de alzheimer, e, uso do composto ou de uma pró-droga do mesmo
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
BRPI0914902A2 (pt)	2017-06-20	composição farmacêutica e método para tratamento de mal de parkinson
PT2796457T (pt)	2016-07-14	Genz 112638 para o tratamento de doença de gaucher ou de fabry em terapia de associação
BR112013011480A2 (pt)	2016-08-09	método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI1014390A2 (pt)	2016-04-05	composto de sal de amônio quaternário, composição medicinal, e, agente preventivo ou terapêutico
BRPI0812740A2 (pt)	2016-07-19	composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de um distúrbio do sistema nervoso central de um corpo de animal vivo.
BRPI0718041A2 (pt)	2015-05-12	Antagonista do receptor da angiotensina ii para prevenção ou tratamento de doenças sistêmicas em gatos
BR112013011968A2 (pt)	2016-08-30	composição farmacêutica, métodos de tratamento e usos da mesma
BRPI0919231A2 (pt)	2018-01-09	agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
BRPI0907974A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI1007092A2 (pt)	2015-08-18	"derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas, método para prevenção ou tratamento de doença e método de produção de derivados de hidroxamato"
BRPI0818841A2 (pt)	2015-04-22	Compostos para uso em formação de imagem, diagnóstico e/ou tratamento de doenças do sistema nervoso central ou de tumores
BR112012002265A2 (pt)	2016-06-14	composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
BR112012002246A2 (pt)	2019-09-24	composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
BR112013001297A2 (pt)	2017-11-21	composições farmacêuticas e respectivo uso e método de tratamento de doença ou condição respiratória
ZA201203281B (en)	2013-06-26	Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals